{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059544","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.517123+00:00","generated_at":"2026-06-02T00:56:58.640541+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Enliven Therapeutics Q1 net loss $22.7M; ELVN-001 Phase 1 shows 44% MMR at 12 weeks","bullets":["Net loss of $22.7M for Q1 2024 vs $14.7M in Q1 2023; cash, equivalents & marketable securities $320.5M.","ELVN-001 Phase 1 proof-of-concept: 44% (7/16) cumulative MMR rate by week 12 in response-evaluable CML patients.","Entered $90M PIPE financing from new/existing investors; expected cash runway into late 2026.","Appointed Dr. Lori Kunkel to Board of Directors.","Activated first site for ELVN-002 combo trial with trastuzumab in HER2+ cancers; first dosing expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059544","json":"https://secwatch.observer/filing/0000950170-24-059544.json","markdown":"https://secwatch.observer/filing/0000950170-24-059544.md","text":"https://secwatch.observer/filing/0000950170-24-059544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000095017024059544/0000950170-24-059544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000095017024059544/elvn-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:56:58.640541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2064e0428165acafedd537a4bceac2c674c3e7c0","claim":"Enliven Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $22.7 million.","evidence_excerpt":"Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672619/000095017024059544/0000950170-24-059544-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$22.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}